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Type 1 diabetes (T1D) results from the destruc-
tion of pancreatic  cells by autoimmune T cells 
(Tisch and McDevitt, 1996). The etiology of 
the autoimmune process is unknown but it has 
been postulated that T cells with specificity for 
poorly agonistic self-peptides escape negative se-
lection  in  the  thymus  and  mount  an  auto-
immune attack in peripheral tissue (Fairchild 
et al., 1993; Liu et al., 1995; Garcia et al., 1999; 
Hahn  et  al.,  2005;  Stadinski  et  al.,  2010; 
Wucherpfennig and Sethi, 2011). Accordingly, 
T cell receptors of autoimmune T cell clones 
were  found  to  bind  to  peptide–MHC  com-
plexes with low affinity and/or unusual topol-
ogy  (Sethi  et  al.,  2011;  Wucherpfennig  and 
Sethi,  2011).  Moreover,  weak  interactions  of 
self-ligands with MHC molecules are caused by 
partially filling the MHC binding groove or by 
the use of unfavored binding registers (Stadinski 
et al., 2010). The result in both scenarios is a TCR 
ligand with relatively poor agonistic activity.
Here, we propose a different hypothesis con-
cerning the development of autoimmune disease 
that also offers preventive measures. We argue that 
poor agonistic ligands not only permit escape 
from “recessive” tolerance, i.e., negative selection 
in the thymus, but that such ligands also fail to   
efficiently induce “dominant” tolerance i.e., 
Foxp3+ T reg cells that can control the disease in   
peripheral tissue. The hypothesis is based on previ-
ous observations that when applied under sub-
immunogenic conditions, TCR ligands of high 
agonist activity convert naive but not activated   
T cells into stable T reg cells expressing Foxp3 
(Apostolou and von Boehmer, 2004; Kretschmer 
et al., 2005; Polansky et al., 2008). The notion is in 
line with experimental data showing an essential 
lifelong function of Foxp3+ T reg cells in prevent-
ing autoimmune disease (Fontenot et al., 2005; 
Lahl et al., 2007). In addition, it offers a straight-
forward  strategy  to  prevent  autoimmunity  by 
converting T  cells  with  specificity  for  poorly   
agonistic self-ligands into Foxp3+ T reg cells by 
delivering  strongly  agonistic  mimetopes  of  the 
self-ligands. In models unrelated to autoimmunity, 
dominant tolerance has best been achieved with 
strong agonist ligands (Kretschmer et al., 2005; 
Daniel et al., 2010), even in WT mice where   
antigen-specific naive T cells are rather infrequent 
(Verginis et al., 2008). Here, we test whether in 
the case of autoimmune T1D, where insulin   
represents an essential autoantigen (Nakayama   
et al., 2005), subimmunogenic delivery of strongly   
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Type 1 diabetes (T1D) results from the destruction of insulin-secreting pancreatic  cells 
by autoreactive T cells. Insulin is an essential target of the autoimmune attack. Insulin 
epitopes recognized by diabetogenic T cell clones bind poorly to the class II I-Ag7 molecules 
of nonobese diabetic (NOD) mice, which results in weak agonistic activity of the peptide 
MHC complex. Here, we describe a strongly agonistic insulin mimetope that effectively 
converts naive T cells into Foxp3+ regulatory T cells in vivo, thereby completely preventing 
T1D in NOD mice. In contrast, natural insulin epitopes are ineffective. Subimmunogenic 
vaccination with strongly agonistic insulin mimetopes might represent a novel strategy to 
prevent T1D in humans at risk for the disease.
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for MHC pockets p1, p4, p6, and p9 are shown in subscript 
and are marked blue for the binding register 3) that is recog-
nized by most T cell clones from diabetic mice, including the 
T cells used in this experiment (Stadinski et al., 2010). Accord-
ingly, the arginine residue (R22) in the natural peptide that in 
this reading frame confronts another arginine in the positively 
charged p9 pocket of I-Ag7 was replaced with glutamic acid 
(Fig. 1 a, R22E). Both the full-length and the core peptide 
with the mutated residue induced much stronger proliferation 
(40-fold at 0.1 µg/ml), as well as conversion into Foxp3+ 
T reg cells (3-fold) when used under appropriate subimmuno-
genic conditions, i.e., either applied by subcutaneous peptide 
infusion using osmotic minipumps (5 µg/d for 14 d) or by a 
subcutaneous single shot injection using DEC205 fusion anti-
bodies (40 ng/mouse; Fig. 1). The mutated core peptide was 
labeled mimetope 3 and used in all further experiments.
T1D prevention and insulin autoantibodies
Insulin autoantibodies (IAAs) correlate with insulitis, the de-
velopment of T1D, and T cell activation (Yu et al., 2000), the 
latter interfering with the effective conversion of T cells into 
Foxp3+ T reg cells (Fig. 2 a). We used the recently developed 
highly specific and sensitive method of a competitive IAA   
assay that has overcome previous problems in IAA detection 
(Babaya et al., 2009). In NOD mice, IAA can be detected as 
early as 15 d after birth (Reddy et al., 1988; Michel et al., 
1989) with few mice exhibiting very high titers at the age of 
4 wk, correlating with early onset of disease (Yu et al., 2000). 
To correlate IAA indices and possible effects of insulin epi-
topes and mimetopes on T1D prevention, IAA indices were 
determined in NOD mice at the age of 4 (before vaccination) 
and 6 wk (after vaccination). As shown in Fig. 2 there was in-
deed a correlation of IAA indices and development of diabe-
tes, in that mice with higher indices developed diabetes earlier. 
Moreover, although the natural epitope afforded no protec-
tion, the mimetope 3 prevented the onset of T1D in the mice 
with moderate IAA (indices <1). Only in mice that already 
harbored high IAA with indices >1 at 4 wk of age was the 
mimetope 3 unable to completely prevent disease develop-
ment. This is best explained by the assumption that mice with 
high indices of IAA already contain too many activated T cells 
that cannot be efficiently converted into Foxp3+ T reg cells 
(Fig. 2 a). Analysis of IAA before and after vaccination showed 
that subimmunogenic treatment with mimetope 3 substan-
tially decreased IAA indices (Fig. 2 d), which is consistent 
with inducing immunosuppression. At 4 wk of age, 95% of 
mice exhibited IAA with indices <1 (moderate levels of IAA), 
and therefore were included in further experiments.
The protection by mimetope 3 was studied for longer 
time periods (Fig. 3 a), and with varying doses, in the afore-
mentioned mice. A dose of 5 µg/d of mimetope 3 protected 
mice for 40 wk (which is when animals were sacrificed for 
analyses), whereas the same dose of the natural epitope had 
very little beneficial effect in preventing diabetes develop-
ment. NOD mice were protected from developing T1D for 
up to 70 wk when they were followed for longer periods. 
agonistic insulin mimetopes can convert naive T cells into pro-
tective Foxp3+ T reg cells and thereby prevent T1D.
Our results show that dominant tolerance to essential in-
sulin epitopes indeed fails in T1D and that its establishment 
by Foxp3+ T reg cell conversion using a strong agonistic in-
sulin mimetope is capable of completely preventing the onset 
of T1D in the nonobese diabetic (NOD) mouse.
RESULTS
Agonist and T reg cell conversion activity of insulin epitopes 
and mimetopes
T cells expressing a transgenic TCR specific for the insulin B 
chain epitope 9–23 presented in the context of I-Ag7 MHC 
class II molecules (Jasinski et al., 2006) were used to determine 
the activities of several insulin epitopes and mimetopes (Fig. 1). 
These cells represent a subset of T cells that recognize the 
weakly agonistic natural epitope because high doses of the   
natural epitope are required to induce proliferation. The poor 
agonistic activity is likely to result from the weak binding of 
the natural insulin epitope to I-Ag7 in the third MHC-binding 
register (Stadinski et al., 2010; Fig. 1 a, MHC-binding residues 
Figure 1.  Agonist activity of insulin B chain epitopes and mime-
topes. (a) One-letter amino acid codes are shown for insulin B chain epi-
topes and mimetopes. MHC-binding residues are shown in subscript and 
in blue for binding register 3. Residues 9–11, which do not contribute to 
MHC binding, are shown in gray. (b) Analysis of proliferation of insulin 
B:9-23–specific TCR transgenic T cells stimulated with epitopes and mime-
topes. Results are the averages ± SEM of triplicate wells from four 
independent experiments. (c) Agonist and T reg cell conversion activity.  
In vivo T reg cell conversion using naive CD4+ insulin B:9-23 TCR transgenic  
T cells transferred into congenic NOD Thy1.1+ mice at 4 wk of age. Error 
bars show percentages of Foxp3+ T reg cells (± SEM from three indepen-
dent experiments; n = 4 per group) at 2 wk after injection of cells and 
infusion of peptide. Peptide was delivered either by a 2-wk infusion pe-
riod using osmotic minipumps or by a single i.p. injection of DEC205 fu-
sion antibody. *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus insulin B:9-23.JEM Vol. 208, No. 7 
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Figure 2.  Efficacy of Foxp3+ T reg cell vaccination as a function of IAA levels at 4 wk. (a) Naive CD4+CD25CD62LhiCD44lowFoxp3GFP cells or 
activated CD4+CD25CD62LloCD44hiFoxp3GFP cells were subjected to in vitro conversion assays (-CD3 + -CD28) in the presence or absence (= control) of 
TGF. After 3 d, Foxp3 expression was analyzed by FACS. Figure shows a representative dot plot from four independent experiments performed in tripli-
cates per treatment group. (b and c) NOD mice were infused with insulin B:9-23 peptide (b) or insulin mimetope 3 (c) at 4–6 wk of age. IAA indices were 
measured at 4 wk of age, before vaccination. Vertical lines indicate the lower detection limit for IAAs. n = 12 for each group from three independent ex-
periments. (d) IAA indices in NOD mice were measured at 4 wk of age (before vaccination) and at 6 wk of age (after vaccination). Nonvaccinated control 
mice were infused with PBS. Mice with IAA indices <1 were included. Bars show averages ± SEM of IAA indices. n = 8 from two independent experiments. 
*, P < 0.05; **, P < 0.01; ***, P < 0.001 versus insulin B:9-23.
Figure 3.  Development of diabetes. (a) Cumulative diabetes inci-
dence in NOD mice, nonvaccinated, vaccinated with insulin B:9-23 or 
insulin mimetope 3 at 4–6 wk of age. n = 12 from three independent 
experiments. (b) Cumulative diabetes incidence of NOD mice, nonvacci-
nated, vaccinated with insulin B:9-23 or insulin mimetope 3 at 12–14 wk 
of age. n = 6 from two independent experiments. **, P < 0.01; ***, P < 0.001 
versus insulin B:9-23.
Figure 4.  Dose response of insulin epitope and mimetope. (a) Cumu-
lative diabetes incidence in NOD mice that were nonvaccinated, vac-
cinated with insulin B:9-23, or vaccinated by insulin mimetope 3 at 4–6 
wk of age (doses 2.5–20 µg/d). n = 6 from two independent experiments. 
(b) In vivo T reg cell conversion using naive CD4+ insulin B:9-23 TCR 
transgenic T cells transferred into congenic NOD Thy1.1+ mice. Percent-
ages of Foxp3+ T reg cells (± SEM, n = 6 from two independent experi-
ments) at 2 wk after vaccination with indicated doses of peptide. *, P < 
0.05; **, P < 0.01; ***, P < 0.001 versus insulin B:9-23.1504 Tolerogenic vaccination prevents type 1 diabetes. | Daniel et al.
When the natural epitope and the mimetope were titrated 
(Fig. 4), it became clear that daily doses of mimetope 3 (2.5 or 
20 µg/d) applied at 4–6 wk of age were somewhat less effective 
in achieving complete protection from diabetes development 
than 5 and 10 µg/d doses, whereas none of the doses of the 
natural epitope afforded significant protection from disease 
(Fig. 4 a). This is consistent with results that were obtained by 
testing various doses on Foxp3+ T reg cell conversion; none of 
the doses of the natural epitope (including 40 µg/d) resulted 
in Foxp3+ T reg cell conversion exceeding 15% of naive   
T cells. Mimetope 3 at a dose of 5 and 10 µg/d yielded be-
tween 40 and 50% of converted Foxp3+ T reg cells, whereas a 
dose of 20 µg/d resulted in <30% conversion (Fig. 4 b).
We then tested whether the rapamycin analogue everol-
imus had an effect on the development of T1D in normal 
NOD mice and in mice that had received the natural epitope 
or mimetope 3. As shown in Fig. 5, everolimus indeed de-
layed the onset of T1D in otherwise untreated mice and mice 
receiving the natural epitope, whereas no T1D developed in 
mice that also received mimetope 3. These data suggest that 
the simultaneous application of everolimus and mimetope 
represents a powerful tool for the prevention of T1D (see in-
sulitis scores in Fig. 6) because everolimus prevents the im-
mediate activation of effector cells as long as naive T cells are 
not yet converted while enhancing the conversion of naive 
T cells into T reg cells in vivo.
It  has  been  established  that  the 
extent of infiltration by mononuclear 
cells in pancreatic islets of NOD mice 
corresponds to the extent of glycemia. 
Mice that have been treated with the 
natural epitope exhibited mostly strong 
(malignant) infiltration, whereas mime-
tope 3-treated mice showed mainly 
periinsulitis  or  partial  insulitis  with 
many morphologically intact  cells 
producing  insulin,  resulting  in  nor-
moglycemia (Fig. 6 and data shown 
in Fig. 7). Quantitative assessment of 
a larger number of samples yielded 
insulitis scores as also shown in Fig. 6. 
Mimetope 3-vaccinated mice exhibited 
significantly lower insulitis scores in 
comparison to untreated mice or mice 
that had received the natural insulin 
epitope. The combined application of 
Moreover, in mice with moderate levels of IAA, vaccination 
with mimetope 3 but not the natural insulin epitope was still 
effective in preventing the development of T1D, even when 
the peptide infusion was started in 12-wk-old mice (Fig. 3 b).
Figure 5.  Impact of the mTOR inhibitor everolimus on develop-
ment of diabetes. Cumulative diabetes incidence of NOD mice treated 
with a combination of the natural insulin epitope or the mimetope plus 
everolimus (3 mg/kg i.p. for 14 d) or everolimus alone. n = 12 from three 
independent experiments. *, P < 0.05 versus insulin B:9-23 + everolimus.
Figure 6.  Histopathological evaluation of 
pancreas sections from either nonvacci-
nated or vaccinated NOD mice at the age 
of 20 or 40 wk. Representative hematoxylin 
and eosin–stained paraffin-embedded pan-
creas sections are shown in a and b. Bars,  
100 µm. Grading of insulitis of the various 
treatment groups is shown in c and d. n = 12 
from three independent experiments.JEM Vol. 208, No. 7 
Article
1505
producing  cells, which was further enhanced when everol-
imus was co-injected. The data of percentages of Foxp3+ 
T reg cells in pancreas-infiltrating CD4+ T cells confirm the 
superior effect of the mimetope in inducing Foxp3+ T reg 
cells as seen from absolute numbers of T reg cells (Fig. 8). It 
is clear that injection of the natural epitope also yielded a 
modest increase in Foxp3+ cells that was obviously insuffi-
cient to protect from T1D (Fig. 3 and Fig. 4). In addition, in 
NOD Foxp3 GFP reporter mice vaccination with mime-
tope 3 resulted in the highest percentages and most GFP+ 
cells in pancreatic lymph nodes (Fig. 8 b).
Because activated Foxp3+ T reg cells do not home prop-
erly to pancreatic lymph nodes (Tarbell et al., 2004, 2007), we 
did not attempt to transfer T reg cells from vacci-
nated mice to assess dominant tolerance. Instead, we 
used a previously described protocol (Sundstedt et al., 
2003; Tarbell et al., 2004, 2007) of transferring 
CFSE-labeled, insulin-specific T cells into differently 
vaccinated mice and monitoring their prolifera-
tion. If dominant tolerance was established, prolif-
eration should be suppressed and recessive forms of 
tolerance like deletion or anergy should not result 
in  suppression  of  proliferation  because  recessive 
tolerance induced by strong agonist ligands is pre-
ceded by proliferation (Lanoue et al., 1997). Fig. 9 
shows that mimetope 3–vaccinated mice displayed 
suppression  of  proliferation  of  insulin-specific   
T cells when the proportion of cells with diluted 
CFSE label was determined (Fig. 9a-c). Suppression 
of insulin-specific effector cells in mimetope 3–
treated mice could be detected in 8- and 30-wk-
old mice (Fig. 9, a–c). In additional experiments, 
we transferred CFSE-labeled, polyclonal-activated 
CD4  effector T  cells  purified  from  pancreatic 
lymph nodes of newly diabetic mice into mime-
tope-vaccinated NOD mice. It became clear that, 
in contrast to the natural epitope, vaccination with 
the mimetope resulted in suppression of polyclonal 
effector cells (Fig. S1).
Finally, we determined the proliferative response 
of ex vivo cells from pancreatic lymph nodes from un-
treated, natural epitope–, or mimetope 3–vaccinated 
mimetope 3 and everolimus resulted in a further reduction 
of insulitis scores, underlining a superior effect in the preven-
tion of T1D when used together (Fig. 6 and Fig. 7).
Dominant tolerance in normoglycemic mice
To test whether the observed protection was indeed caused 
by dominant tolerance executed by converted Foxp3+ T reg 
cells the number of Foxp3+ T reg cell was determined in 
several  experimental  mice. To  this  end,  NOD  or  NOD 
Foxp3 GFP reporter mice that were untreated or injected 
with natural epitope or mimetope 3 were analyzed. As shown 
in Fig. 7 and Fig. 8 mice vaccinated with mimetope 3 always 
exhibited the highest number of Foxp3+ cells and insulin-
Figure 7.  Analysis of Foxp3 expression in 30-wk-old 
NOD mice. Foxp3 immunohistochemistry in pancreatic 
cryosections. (a) Co-stainings of CD4 (green) and Foxp3 (red) 
expression in the respective treatment groups (b–d). Repre-
sentative co-stainings of insulin (green) and Foxp3 (red) 
expression in pancreatic sections of mice that were non-
vaccinated (b), vaccinated with insulin B:9-23 (c), and vacci-
nated with insulin mimetope 3 (d). n = 8 per group from two 
independent experiments.Bars, 100 µm. (e) Quantification of 
Foxp3+ cells in pancreatic sections as described in b–d. Bars 
show Foxp3+ cells per high-power field (± SEM from two 
independent experiments; n = 8 per group). *, P < 0.05;  
**, P < 0.01 versus insulin B:9-23.1506 Tolerogenic vaccination prevents type 1 diabetes. | Daniel et al.
Foxp3+ T reg cells was similar in all mice, indicating the ab-
sence of recessive tolerance. When the cytokine response of 
effector cells was analyzed, it became clear that there were 
no differences in IL-10 production, whereas vaccination with 
mimetope 3 resulted in reduced secretion of IFN- and 
IL-17 (Fig. 10).
Collectively, these results indicate that in contrast to the 
natural insulin epitope, vaccination with mimetope 3 results 
in the highest number of stable Foxp3+ 
cells that suppress the proliferation of 
IFN-– and IL-17 cytokine-secreting, 
insulin-specific effector cells.
DISCUSSION
Vaccination with insulin or its mime-
topes  has  been  tested  previously,  to 
prevent  or  treat T1D  using  mucosal 
exposure or in the presence of adju-
vant such as cholera toxin B subunit or 
IFA (Zhang et al., 1991; Daniel and 
Wegmann, 1996; Harrison et al., 1996; 
Bergerot et al., 1997; Chen et al., 2001; 
NOD Foxp3 GFP reporter mice in the presence or absence 
of Foxp3+ T reg cells. As shown in Fig. 9 d, Foxp3+ T reg cells 
from mimetope 3–vaccinated mice completely suppressed 
proliferation of effector cells, reflecting an enrichment of 
insulin-specific cells within the Foxp3+–T reg cell popula-
tion, whereas T reg cells from nonvaccinated animals or mice 
treated with the natural epitope were less suppressive. Impor-
tantly, the proliferation of effector cells in the absence of 
Figure 8.  Foxp3+ T reg cells in pancreata 
and pancreatic lymph nodes of NOD mice. 
(a) Percentages and absolute numbers of 
Foxp3+ T reg cells in pancreatic islet–infiltrating 
T cells of 30-wk-old NOD mice from the re-
spective treatment groups, analyzed by flow 
cytometry. Bars represent means ± SEM from 
three independent experiments. n = 4 per 
group. (b) Percentages and absolute number of 
CD4 T cells expressing Foxp3 GFP in pancreatic 
lymph nodes from 20-wk-old NOD Foxp3-GFP 
reporter mice, analyzed by flow cytometry. Bars 
represent means ±SEM from two independent 
experiments, n = 4 per group. Mice were vac-
cinated at 4–6 wk of age.
Figure 9.  Analysis of dominant tolerance 
in vaccinated NOD mice. CFSE dilution pro-
files of insulin B:9-23 TCR transgenic T cells at 
day 4 after transfer into nonvaccinated or 
vaccinated 8- (a) or 30-wk-old (b) NOD mice. 
(c) Percentages of divided insulin B:9-23 TCR 
transgenic T cells after transfer into the vac-
cination groups as described in a and b. Bars 
represent means ± SEM from two indepen-
dent experiments. n = 4 per group. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001 versus insulin B:9-23. 
(d) Analysis of proliferation of T cells from 
pancreatic lymph nodes of NOD Foxp3-GFP 
reporter mice at 20 wk, vaccinated with either 
insulin B:9-23 or insulin mimetope 3 at 4–6 
wk of age. Proliferation before or after deple-
tion of Foxp3+ T cells in response to the insu-
lin mimetope was analyzed. Results are the 
means ± SEM from two independent experi-
ments. n = 4 per group.JEM Vol. 208, No. 7 
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to convert naive T cells through appropriate antigenic stimu-
lation under subimmunogenic conditions into Foxp3+ T reg 
cells offers a convenient strategy to induce antigen-specific 
dominant tolerance for several reasons. Foxp3+ T reg cell vac-
cination requires only a single epitope because the induced   
T reg cells suppress immune responses of T cells to antigen from 
the same source through bystander suppression (Verginis et al., 
2008), whereby the vicinity to antigen presenting cells is rel-
evant. An additional advantage is that this mode of tolerance 
can be easily induced in the mature immune system by sub-
immunogenic delivery of antigen (Verginis et al., 2008; Daniel 
et al., 2010), i.e., in the absence of general immunosuppres-
sion that can have fatal consequences. The induced Foxp3+  
T reg cells are stable (Polansky et al., 2008) and maintain their 
function even in an immunogenic context (Rubtsov et al., 
2010) because reencounter of antigen causes neither loss of   
T reg cells nor loss of their activity (Klein et al., 2003).
Because the method is preventive, one should aim at a 
cohort of individuals with elevated risk of developing T1D. 
IAAs precede the development of T1D (Ziegler et al., 1989; 
Yu et al., 2000), i.e., most diabetes patients have IAA before 
T1D onset, therefore individuals with high-risk 
MHC alleles, such as HLA-DQ8 and DQ2, and 
moderate levels of IAA represent a well-defined 
population to vaccinate by this method.
The use of strongly agonistic ligands applied 
under  subimmunogenic  conditions  results  in 
complete protection from autoimmune disease 
development; this protection from autoimmune 
diabetes development has not previously been 
achieved with natural epitopes, irrespective of 
dose and mode of application, which is consis-
tent with the finding that insulin-specific T cells 
in NOD mice exhibit specificity for poorly ag-
onistic ligands (Stadinski et al., 2010). It is also 
consistent  with  the  belief  that  high-affinity 
TCR ligands are the best inducers of T reg cells, 
although in these short-term experiments using 
models uunrelated to autoimmunity only TCR 
Alleva et al., 2002; Aspord and Thivolet, 2002; Martinez et al., 
2003). The goal of these attempts was not to induce Foxp3+ 
T reg cells, and they afforded only incomplete protection, per-
haps because of the fact that such maneuvers shifted the Th1 
to Th2 ratio (Alleva et al., 2002). This would explain why with 
our tolerogenic vaccination protocol we see a drop in IAA in-
dices, whereas in previous vaccination protocols an increase 
was noted (Orban et al., 2010). However, none of the previ-
ously established protocols reached the level of protection 
noted in the approach presented here and ensuing clinical tri-
als using natural insulin epitopes were largely unsuccessful.
The findings demonstrated here support the hypothesis 
that weakly agonistic self-ligands recognized by autoreactive 
T cells fail to efficiently induce dominant tolerance. We there-
fore propose a novel concept of extrathymic Foxp3+ T reg 
cell conversion in autoimmune disease settings by applying 
minute amounts of strongly agonistic mimetopes of critical 
autoantigens, such as insulin in T1D. In contrast, natural in-
sulin epitopes with poor agonistic activity that are recognized 
by diabetogenic T cells, irrespective of the applied dose, are 
ineffective in inducing stable Foxp3+ T reg cells. The ability 
Figure 10.  Characterization of effector T cells  
isolated from pancreatic lymph nodes of NOD 
Foxp3-GFP reporter mice at 20 wk. The mice were 
nonvaccinated, vaccinated with insulin B:9-23, or insulin 
mimetope 3 at 4–6 wk. Cytokine expression in T effector 
cells after depletion of Foxp3+ T cells in response to the 
insulin mimetope 3 was analyzed by intracellular staining 
(a) or by ELISA (b). *, P < 0.05 versus control. Representa-
tive dot plots are shown. Data are representative of two 
independent experiments. n = 4 per group. Expression of 
the lineage-specific transcription factors as assessed by 
intracellular staining is shown in c. Cells are gated on 
CD4+ T cells. Black solid line, nonvaccinated control; red 
solid line, insulin B:9-23 vaccinated; blue dotted line, 
insulin mimetope 3 vaccinated. Results are the  
means ± SEM from two independent experiments. n = 4 
per group.1508 Tolerogenic vaccination prevents type 1 diabetes. | Daniel et al.
and in accordance with the guidelines of the Animal Care and Use Committee 
of the Dana Farber Cancer Institute.
Histopathology of mouse NOD pancreata. Pancreata were fixed in 
Bouin’s solution and embedded in paraffin, and serial sections were stained 
with hematoxylin and eosin for general morphology. Histology and scoring 
of  insulitis  in  pancreatic  sections  were  executed  as  previously  described 
(Jaeckel et al., 2004; Krishnamurthy et al., 2006). Pancreatic islets were as-
signed scores as follows: 0, intact islets/no lesions; 1, periislet infiltrates; 2, <25% 
islet destruction; 3, >25% islet destruction; 4, complete islet destruction.
Peptides. All peptides with amino acid sequences described in Fig. 1 a were 
synthesized at New England Peptide.
IAA assay. Mouse high specificity/sensitivity competitive IAA assays in sera 
from NOD mice were performed in an ELISA format, as described previ-
ously (Babaya et al., 2009). In brief, high binding 96-well plates (Costar) 
were coated with human (recombinant) insulin (100 U/ml; Humulin; Lilly) 
overnight at 4ºC. Unspecific-blocking was done using PBS containing 2% 
BSA for 2 h at room temperature. Preincubated serum (diluted 1:10) with or 
without insulin competition was added and incubated for 2 h at room tem-
perature. After 4 wash steps, biotinylated anti–mouse IgG1 (Abcam), diluted 
1:10,000 in PBS/BSA was added for 30 min at room temperature. After 
washing the plate, horseradish peroxidase–labeled streptavidin was added for 
15 min. The plate was washed 5 times, and TMB substrate solution was 
added (OptEIA reagent set; BD). Each sample was run in duplicate with and 
without competition using human insulin. For each sample, an index was 
calculated based on the mean of the results.
Isolation of pancreatic islets and infiltrating T cells. Cells were puri-
fied from mouse pancreata after in situ pancreas perfusion with collagenase, 
pancreas digestion, and islet purification using previously described protocols 
(Trembleau et al., 1995; Szot et al., 2007; Li et al., 2009). Purified islets were 
washed and subsequently selected by hand or separated by Ficoll gradient.
In vitro T cell proliferation assay. Assays were performed in round-
bottom 96-well tissue culture plates. CD11c+ DCs from NOD mice were 
used as antigen-presenting cells and were purified using anti-CD11c+ mag-
netic beads (Miltenyi Biotec; Daniel et al., 2011). Thymidine incorporation 
of stimulated CD4+TCR+-enriched insulin B:9-23 TCR transgenic T cells 
or of T cells purified from pancreatic lymph nodes of nonvaccinated or vac-
cinated NOD Foxp3 GFP reporter mice in response to the insulin mimetope 
was analyzed by scintillation counting after the addition of [3H]thymidine for 
the last 12 h of a 70-h culture period.
Analyses of dominant tolerance. CD4+ insulin B:9-23 TCR transgenic 
T cells were labeled with CFSE at 2 µM and incubated for 4 min at 37°C in 
PBS plus 0.1% BSA. Labeled cells were adoptively transferred i.p. into T reg 
cell–vaccinated 8- or 30-wk-old NOD female mice, followed by i.p. co-
injection with insulin B:9-23 peptide (15 µg/mouse). Analysis of CFSE dilu-
tion was done 4 d later in pancreatic lymph nodes using flow cytometry. 
Concentrations of IL-10, IFN-, and IL-17 were analyzed by mouse ELISA 
sets (OptEIA; BD or R&D Systems).
Immunohistochemistry. Immunohistochemistry was performed essentially 
as previously described (Weigmann et al., 2008), with the following changes:   
10 µm cryosections from pancreatic specimens of NOD mice were stained for 
Foxp3 with rat antibody (FJK-16s; eBioscience), rabbit anti-insulin antibody 
C27C9 (Abcam), and mouse anti-CD4 antibody (mAb51312; Abcam). Tissues 
were fixed in ice-cold acetone, followed by methanol blocking, biotin/avidin-
blocking (Vector Laboratories), and protein-blocking reagent (Roth) for elimina-
tion  of  unspecific  background  staining.  Sections  were  permeabilized  with 
Perm-Medium B (ADG), followed by incubation with primary antibodies. Sec-
tions incubated with isotype-matched control antibodies served as negative 
contact residues were modified (Gottschalk et al., 2010). The 
validity of the approach to create higher affinity TCR ligands 
appears to be limited to TCR transgenic systems (Gottschalk 
et al., 2010), as it is unlikely that a peptide that forms a higher 
affinity ligand for a given TCR will also form a higher affinity 
ligand for polyclonal T cell populations reacting with the 
same peptide.
Subimmunogenic doses of strongly agonistic mimetopes 
appear mandatory to achieve complete protection by immuno-
suppression. In contrast, high immunogenic doses of li-
gands lead to the activation of the PI3K–Akt–mTOR pathway 
(Merkenschlager and von Boehmer, 2010), which could in-
terfere with extrathymic Foxp3 induction (Sauer et al., 2008). 
Recent studies show that Foxo proteins, which are inactivated 
by Akt, drive Foxp3 expression. These studies could explain 
the negative regulation of Foxp3 by the PI3K–Akt network 
(Merkenschlager and von Boehmer, 2010) after strong T cell 
activation. The best Foxp3+ T reg cell conversion is seen in   
T cells that undergo only limited proliferation, whereas higher 
doses of agonists result in more extensive proliferation and di-
minished Foxp3+ T reg cell conversion (Kretschmer et al., 
2005). In support of these conclusions, robust T cell activation 
has  been  shown  to  negatively  impact  on  the  extrathymic   
T reg cell generation based on a cell-cycle dependent mainte-
nance of a silenced state of the Foxp3 locus (Josefowicz et al., 
2009). This mode of immunosuppression differs from meth-
ods  that  induced  increased  levels  of  IL-10  production  by 
CD25 cells (Sundstedt et al., 2003).
The NOD mouse appears to represent a faithful model of 
human disease because it is controlled by the same genetic factors, 
such as MHC class II genes (Suri et al., 2005, 2008) and levels 
of intrathymic insulin expression (Pugliese et al., 1997; Jaeckel 
et al., 2004). Epitopes recognized by human CD4 T cells include 
the insulin B:9-23 (Alleva et al., 2001) peptide, which is identical 
to that of mouse insulin. Such cells were reported in cohorts of 
people at risk of developing T1D and with recent onset of 
T1D, but not in control subjects (Alleva et al., 2001). Human 
class II HLA-DQ8 and DQ2 alleles bear striking resemblance to 
the mouse class II I-Ag7 allele that confers susceptibility (Lee 
et al., 2001) with a positively charged p9 MHC-binding pocket 
that distinguishes the DQ8 and DQ2 alleles from other class II 
alleles that do not confer susceptibility. Thus, it seems reasonable 
to explore the possibility that the scenario as revealed in the 
NOD mouse also applies in human disease.
MATERIALS AND METHODS
Mice. Insulin (B:9-23) TCR transgenic RAG/ NOD mice were previously 
described (Jasinski et al., 2006) and were bred in the facility of the Dana Farber 
Cancer Institute. 4-wk-old female NOD mice were purchased from Taconic. 
Thy1.1+ congenic NOD mice and NOD Foxp3 GFP reporter mice were ob-
tained from The Jackson Laboratory. Antigen-specific in vivo T reg cell conver-
sion protocols, with or without everolimus treatment, were executed as previously 
described (Daniel et al., 2011). Before T reg cell conversion, mice were tested for 
IAA. Mice with high titers (indices ≥1) were excluded from analyses, as in these 
mice most insulin-specific T cells may already have been activated and hence re-
sistant to T reg cell conversion. Diabetes development was monitored according 
to previously described protocols (Jaeckel et al., 2003, 2004). All animal care and 
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control. Next, samples were incubated with biotinylated secondary IgG antibody 
(Dianova), incubated with streptavidin-HRP, and stained with tyramide-Cy3 or 
tyramide-FITC (Invitrogen) according to the manufacturer’s instructions.
Antibodies  and  flow  cytometry.  mAbs  specific  for  Thy1.1  (OX-7), 
Thy1.2  (53–2.1),  CD4  (RM4-5),  CD25  (PC61),  CD44  (IM7),  CD62L 
(MEL-14), CD127 (A7R34), Foxp3 (FJK-16s), ROR- (AFKJS-9), T-bet 
(eBio4B10), GATA3 (TWAJ), IL-17 (TC11-18H10) and IFN- (XMG1.2) 
were purchased from BD, eBioscience, or BioLegend and were used as bio-
tin, FITC, PE, PE-Cy7, PerCP-Cy5.5, allophycocyanin, allophycocyanin-
Cy7, Alexa Fluor 488 or Pacific blue conjugates. Enumeration of cells and 
acquisition are performed by using FACSAria and FACSDiva software (BD). 
Single-cell data analyses are done by the use of the FlowJo software (Tree 
Star, Inc.).
Statistical  analysis.  Data  were  analyzed  by  one-way  ANOVA  with 
Tukey’s post hoc test or with the Holm-Sidak method for comparison of 
multiple columns. Wilcoxon signed rank test was used to analyze the impact 
of T reg cell vaccination on IAA levels before and after treatment. Cumula-
tive incidence of diabetes was determined by Kaplan-Meier estimates, and 
statistical analysis of difference was determined by log-rank test. A value of   
P < 0.05 was considered significant. Analyses were done using SigmaStat 3.5 
(Systat Software).
Online supplemental material. Fig. S1 shows the analysis of dominant tol-
erance to polyclonal effector T cells in vaccinated NOD mice. Online sup-
plemental material is available at http://www.jem.org/cgi/content/full/ 
jem.20110574/DC1.
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